Victoza (liraglutide [rDNA origin]) Injection: REMS – Risk of Thyroid C-cell Tumors, Acute Pancreatitis

Audience: Endocrinology, Family Practice ISSUE: Novo Nordisk reminded healthcare professionals of important safety information about Victoza (liraglutide [rDNA origin]) injection required in a Risk Evaluation and Mitigation Strategy (REMS). The…

Related posts:

1. Avandia (rosiglitazone): REMS – Risk of Cardiovascular Events Audience: Endocrinology, Cardiology includes Avandia, Avandamet, and Avandaryl [UPDATED 05/18/2011]...
2. Yervoy (ipilimumab): Risk Evaluation and Mitigation Strategy (REMS) – Severe Immune-Mediated Adverse Reactions Audience: Hematology-Oncology ISSUE: Bristol-Myers Squibb informed healthcare professionals about the...